BOSTON--(BUSINESS WIRE)--Genialis, a leader in applied data science for the development of precision medicines, today announced together with the Bioinformatics Laboratory at the University of Ljubljana that the organizations have entered into a Sponsored Research Agreement to develop new algorithms and methods to better assign patients to therapeutic options based on disease subtypes, deepening Genialis’ investment and expertise in machine-learning-based drug discovery.
Cytocom Inc., a biopharmaceutical company specialized in the area of immune-modulation, and Cleveland BioLabs Inc., an innovative biopharmaceutical company developing novel approaches to activate the immune system, have entered into a definitive merger agreement to combine their businesses in an all-stock transaction.
Ontario, Canada is partnering with Biolab Pharma that develops manufactures and commercializes prescription medicine and is a leader in cardiology and dermatology drugs .